BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) has earned a consensus rating of “Moderate Buy” from the eleven brokerages that are covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Russell Investments Group Ltd Invests $29,000 in BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.